Dare Bioscience
DARE
Market cap $21.1M

2.38 USD

-0.10

4.03%

At close Jul 30, 4:00 PM EDT

After hours

2.42

+0.04

1.68%

1 day

-4.03%

5 days

-12.50%

1 month

-0.42%

3 months

-19.32%

6 months

-25.86%

Year to date

-26.09%

1 year

-30.41%

5 years

-82.29%

10 years

-99.50%

About: Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Employees: 23

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

0.57% more ownership

Funds ownership: 8.93% [Q4 2024] → 9.51% (+0.57%) [Q1 2025]

1% less capital invested

Capital invested by funds: $2.43M [Q4 2024] → $2.39M (-$34.9K) [Q1 2025]

4% less funds holding

Funds holding: 25 [Q4 2024] → 24 (-1) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for DARE.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about DARE published over the past 30 days

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need it most

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women's arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Crude Oil Moves Lower; Daré Bioscience Shares Jump

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Monday.

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health Exploring Strategic Partnerships to Expand Platform Beyond Reproductive Health

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the “Annual Meeting”) was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting.

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator Welcome to the Conference Call hosted by Daré Bioscience to review the company's First Quarter 2025 Financial Results and to provide the Business Update.

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.84 per share a year ago.

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026 In addition to its proprietary Sildenafil Cream formulation, Daré is taking action to make three other solutions for women available commercially, two vaginal probiotics in 2025 and its proprietary monthly hormone therapy in 2026

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Catherine Novack - Jones Trading Douglas Tsao - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference call hosted by Daré Bioscience to review the company's 2024 Financial Results and to provide a Business Update.

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™